Introduction
============

The surgical indications for the removal of an epiretinal membrane (ERM) have not been standardized. The removal of an ERM is helpful for many patients, but the surgical complications, such as endophthalmitis and retinal detachment, can negate the effectiveness of the removal.[@b1-opth-5-147]--[@b3-opth-5-147] Because eyes with an idiopathic ERM have moderately good preoperative vision, the eyes to undergo surgery to remove an ERM should be carefully selected. The selection depends on the patient's symptoms and visual requirements, and the vitreous surgeon's technique. A postoperative decimal best-corrected visual acuity (BCVA) ≥ 1.0 (BCVA Snellen chart ≥ 20/20) is a positive result of removing an idiopathic ERM.[@b4-opth-5-147]--[@b7-opth-5-147]

A 25-gauge transconjunctival sutureless vitrectomy (25G-TSV) and membranectomy for the treatment of idiopathic ERM was first reported in 2002 by Fuji et al.[@b8-opth-5-147],[@b9-opth-5-147] This procedure has evolved and become more common over the years. The main advantage of this technique is that the intraoperative procedure is sutureless, meaning that the wounds are self-sealing. This reduces postoperative ocular pain and discomfort and procedure time, as well as the complications (eg, inflammation, astigmatism). In addition, using a 25G-TSV for the treatment of an idiopathic ERM leads to earlier postoperative visual improvement, compared with conventional 20-gauge vitrectomy.[@b10-opth-5-147],[@b11-opth-5-147] Because 25G-TSV retains the vitreous, the possibility of endophthalmitis has been discussed for many years, but a recent multicenter report of over 40,000 cases indicated no difference.[@b12-opth-5-147]

Though there are many reports of postoperative favorable visual outcomes and visual improvements that may not be exactly defined as decimal BCVA ≥ 1.0, we could not find any reports on preoperative findings that ensure a postoperative decimal BCVA ≥ 1.0 in patients with ERMs. The purpose of this study was to determine the preoperative BCVA and foveal thickness (FT) in eyes with an idiopathic ERM that would help predict a postoperative BCVA ≥ 1.0 following 25G-TSV/membranectomy.

Patients and methods
====================

Participants
------------

This was a retrospective case series of 73 eyes of 73 patients with idiopathic ERMs who underwent 25G-TSV (Alcon Laboratories; Fort Worth, TX, USA)/membranectomy. The inclusion criterion was a clinically detectable idiopathic ERM diagnosed by fundus examination or optical coherence tomography (OCT), causing a decrease of visual acuity or metamorphopsia as reported by the patient; a questionnaire; or Amsler grid findings. The exclusion criteria included prior vitreous surgery, prior intravitreal injection of triamcinolone acetonide or antivascular endothelial growth factor, ocular inflammation, prior scleral buckling, prior trauma, and eyes with complex vitreoretinal disease such as proliferative vitreoretinopathy or proliferative diabetic retinopathy. None of the patients was excluded because of a decimal BCVA \< 0.05. The preoperative demographics of the patients are shown in [Table 1](#t1-opth-5-147){ref-type="table"}.

All of the surgeries were performed at the Surgical Retina Clinic of the Tohoku University Hospital, Sendai, Japan, from July 2006 to November 2008. After the purpose and procedures of the operation were explained, an informed consent was obtained from all patients. The procedures used conformed to the tenets of the Declaration of Helsinki and were approved by the Review Board of the School of Medicine, Tohoku University.

Surgical procedures
-------------------

All surgeries were performed under retrobulbar anesthesia by a single surgeon (HK). A conjunctival peritomy was not made in all cases, and all surgeries were performed with the 25G Accurus Vitrectomy System (Alcon Laboratories). Patients with concomitant lenticular changes had a combined sutureless 25G-TSV and phacoemulsification.

After resecting the vitreal core, about 4 mg of triamcinolone acetonide (TA; Kenacort-A, Bristol-Myers Squibb, Tokyo, Japan) was injected into the vitreous cavity to determine whether a posterior vitreous detachment (PVD) was present. If a PVD was not present, we created a PVD with a 25-gauge cutter. After creating a PVD and removing residual gel, the epiretinal membrane was removed without using any dye. In addition, the internal limiting membrane (ILM) was removed using indocyanine green (ICG; Santen Co., Osaka, Japan) to improve visibility. The ICG crystals were reconstituted in 1.00 mL distilled water to produce a concentration of 25 mg/mL. Further dilutions were made with 19 mL balanced salt solution. Thus, the final concentration of ICG was 1.25 mg/mL, and approximately 0.2 mL of it was injected around the ERM.

Postoperatively, both antibiotics and corticosteroids were injected subconjunctivally in all cases. We used topical nonsteroidal anti-inflammatory drugs for all cases for at least 3 months after the membrane peel.

Measurements of clinical findings
---------------------------------

All of the patients had a complete ophthalmological examination, including BCVA and FT measurements preoperatively and at 6 months postoperatively. The BCVA was determined with a standard Japanese Landolt visual acuity chart. FT was measured by OCT (Zeiss-Humphrey model OCT-3000, Dublin, CA, USA) before and after the 25G-TSV. The retinal thickness of the central fovea was defined as the distance between the ILM and the retinal pigment epithelium and was automatically calculated by the software of the OCT.

Statistical analyses
--------------------

The data are presented as mean ± standard deviation. The significance of the differences between the pre- and post-25G-TSV data was determined by Wilcoxon signed-rank tests. To obtain a postoperative decimal BCVA ≥ 1.0, the distribution of preoperative decimal BCVA and preoperative FT was assessed by Fisher's exact probability test. The decimal BCVA was converted to a logarithm of the minimal angle resolution (logMAR) units for statistical analyses. Spearman's rank correlation coefficient was calculated to determine the correlation between postoperative BCVA (logMAR) and preoperative BCVA (logMAR), and between postoperative BCVA (logMAR) and preoperative FT. A *P* value \< 0.05 was considered to be statistically significant.

Results
=======

A summary of the clinical data is shown in [Table 1](#t1-opth-5-147){ref-type="table"}. The patients included 24 men and 49 women whose mean ± standard deviation age was 67.2 ± 10.4 years. The mean postoperative follow-up period was 9.8 ± 3.5 months with a range of 6--21 months. The mean preoperative BCVA was 0.59 (decimal) or 0.23 logMAR units. Phacoemulsification and aspiration, intraocular lens implantation, and 25G-TSV were performed on 39 eyes (53%), and 25G-TSV only was performed on 34 eyes (47%). In the 22 phakic eyes that had ERM surgery without cataract surgery, there was only one patient whose lens sclerosis progressed postoperatively, and cataract surgery was performed after 5 months from the initial ERM surgery. None of the patients required suturing of the sclerotomy site at the end of the initial surgery.

The mean postoperative BCVA at 6 months was 0.13 ± 0.27 logMAR units, which was significantly better than the preoperative BCVA of 0.23 ± 0.25 logMAR units (*P* \< 0.001, Wilcoxon signed-rank test). The mean postoperative FT was 300 ± 67 μm, which was significantly thinner than the preoperative FT of 371 ± 106 μm (*P* \< 0.001, Wilcoxon signed-rank test).

A summary of the correlations between the BCVA and FT is shown in [Table 2](#t2-opth-5-147){ref-type="table"}. The preoperative BCVA (in logMAR units) was significantly correlated to the preoperative FT (*r* = 0.43, *P* \< 0.001, Spearman's rank correlation coefficient). The postoperative BCVA was significantly correlated with the postoperative FT (*r* = 0.26, *P* = 0.03, Spearman's rank correlation coefficient). The preoperative BCVA was significantly correlated with the postoperative BCVA (*r* = 0.44, *P* \< 0.001, Spearman's rank correlation coefficient, [Figure 1](#f1-opth-5-147){ref-type="fig"}). The preoperative FT was also significantly correlated with the postoperative BCVA (*r* = 0.24, *P* = 0.04, Spearman's rank correlation coefficient, [Figure 2](#f2-opth-5-147){ref-type="fig"}). The mean of the visual improvement (preoperative BCVA -- postoperative BCVA in logMAR units) was 0.10 logMAR units, and this improvement was correlated with the preoperative BCVA (*r* = 0.55, *P* \< 0.001, Spearman's rank correlation coefficient). Thus, the postoperative visual improvement was greater in eyes with initially poorer preoperative vision. However, the postoperative visual improvement was not significantly correlated with the preoperative FT (*r* = 0.21, *P* = 0.07, Spearman's rank correlation coefficient). The reduction of FT (preoperative FT -- postoperative FT) was strongly correlated with the preoperative FT (*r* = 0.80, *P* \< 0.001, Spearman's rank correlation coefficient). The reduction of FT was greater in eyes with thicker preoperative FT. The reduction of FT was also significantly correlated with the preoperative BCVA and postoperative visual improvement (*r* = 0.31, *P* = 0.008, and *r* = 0.24, *P* = 0.04, respectively, Spearman's rank correlation coefficient).

The associations between a preoperative decimal BCVA and a postoperative decimal BCVA ≥ 1.0 are shown in [Table 3](#t3-opth-5-147){ref-type="table"}. A postoperative decimal BCVA ≥ 1.0 was obtained in 29 eyes with a preoperative decimal BCVA ≥ 0.3, but none of the eyes with a preoperative decimal BCVA ≤ 0.2 showed a postoperative decimal BCVA ≥ 1.0. The likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 was 57% (12/21 eyes) in eyes with a preoperative decimal BCVA ≥ 0.9, 47% (7/15 eyes) in eyes with preoperative decimal BCVA of 0.7--0.8, 44% (8/18 eyes) in eyes with preoperative decimal BCVA of 0.5--0.6, and 13% (2/15 eyes) in eyes with preoperative decimal BCVA of 0.3--0.4. The likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 was significantly higher in eyes with a preoperative decimal BCVA ≥ 0.9 than preoperative decimal BCVA of 0.3--0.4 (*P* = 0.008 Fisher's exact probability test). The likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 was significantly higher in eyes with a preoperative decimal BCVA ≥ 0.5 than preoperative decimal BCVA \< 0.5 (*P* = 0.002, Fisher's exact probability test). In addition, there was no significant difference in the likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 between preoperative decimal BCVA ≥ 0.9 and decimal BCVA of 0.7--0.8 and decimal BCVA of 0.5--0.6 ([Table 3](#t3-opth-5-147){ref-type="table"}).

The associations between the preoperative FT and postoperative decimal BCVA ≥ 1.0 are shown in [Table 4](#t4-opth-5-147){ref-type="table"}. The likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 was 21% (6/28 eyes) in eyes with a preoperative FT of ≥400 μm, 56% (14/25 eyes) with a preoperative FT of 300 to 399 μm, 47% (9/19 eyes) with a preoperative FT of 200--299 μm, and 0% (0/1 eyes) in eyes with a preoperative FT of 100--199 μm ([Table 4](#t4-opth-5-147){ref-type="table"}). The difference in the likelihood of obtaining a postoperative BCVA ≥ 1.0 for preoperative FT of 300--399 μm and 200--299 μm was not significant (*P* = 0.40, Fisher's exact probability test). In addition, the likelihood of obtaining a postoperative decimal BCVA ≥ 1.0 in eyes with a preoperative FT of ≥ 400 μm was significantly lower in eyes with a preoperative FT of 300--399 μm (*P* = 0.01, Fisher's exact probability test). However, this relationship was not significant for preoperative FT of 200--299 μm (*P* = 0.06, Fisher's exact probability test). A postoperative decimal BCVA ≥ 1.0 was obtained in 51% (23/45 eyes) of eyes with a preoperative FT \< 400 μm, and the rate of obtaining a postoperative decimal BCVA ≥ 1.0 in eyes with a preoperative FT \< 400 μm was significantly higher than that in eyes with an FT ≥ 400 μm (*P* =0.01, Fisher's exact probability test).

Association between preoperative findings and postoperative decimal BCVA ≥ 1.0 are shown in [Table 5](#t5-opth-5-147){ref-type="table"}. The incidence of obtaining a postoperative decimal BCVA ≥ 1.0 was significantly higher in eyes with preoperative decimal BCVA ≥ 0.5 and FT \< 400 μm (60%) than in eyes with preoperative decimal BCVA ≥ 0.5 and FT ≥ 400 μm (20%; P = 0.03, Fisher's exact probability test) or preoperative BCVA \< 0.5 and FT ≥ 400 μm (7%; P \< 0.001, Fisher's exact probability test).

A summary of the clinical data of the eyes that had a postoperative decimal BCVA ≥ 1.0 or \< 1.0 is shown in [Table 6](#t6-opth-5-147){ref-type="table"}. Statistical analyses on the eyes with a postoperative decimal BCVA ≥ 1.0 or decimal BCVA \< 1.0 showed that the gender, age, lens status, and surgical procedures were not significantly different in the two groups. The mean preoperative BCVA and visual improvement were 0.13 ± 0.15 and 0.18 ± 0.15 logMAR units in the postoperative decimal BCVA ≥ 1.0 group, whereas they were 0.30 ± 0.29 and 0.05 ± 0.23 logMAR units in the postoperative decimal BCVA \< 1.0 group (*P* = 0.004 and P = 0.01, Mann--Whitney *U* test). The mean preoperative FT was thinner in the postoperative decimal BCVA ≥ 1.0 group (*P* = 0.07, Mann--Whitney *U* test), but the difference was not significant, and the mean reduction of FT was significantly lower in the postoperative decimal BCVA ≥ 1.0 group than in the postoperative decimal BCVA \< 1.0 group (*P* \< 0.001, Mann--Whitney *U* test). The mean preoperative FT was 344 ± 73 μm in the postoperative decimal BCVA ≥ 1.0 group, which was not significantly thinner than the 389 ± 121 μm in the postoperative decimal BCVA \< 1.0 group (*P* = 0.07, Mann--Whitney *U* test). However, the FT was reduced by 61 ± 35 μm in the postoperative decimal BCVA ≥ 1.0 group, which was significantly less than the 77 ± 48 μm in the postoperative decimal BCVA \< 1.0 group (*P* \< 0.001, Mann--Whitney *U* test).

Discussion
==========

Our results showed that 25G-TSV and membranectomy used for the treatment of idiopathic ERMs were effective in significantly improving the BCVA and reducing the FT in patients with visual disturbances including decreased BCVA or metamorphopsia. In addition, we found that the postoperative BCVA was correlated with the preoperative BCVA, preoperative FT, and postoperative FT. Approximately more than 50% of the eyes with a preoperative BCVA ≥ 0.5 and a preoperative FT \< 400 μm attained a postoperative decimal BCVA ≥ 1.0. Our results also demonstrated that the preoperative BCVA was significantly correlated not only with the postoperative BCVA but also with the improvement in the BCVA. Because the mean preoperative BCVA was significantly better in the postoperative decimal BCVA ≥ 1.0 group than in the postoperative decimal BCVA \< 1.0 group, a good preoperative BCVA was necessary to obtain a postoperative decimal BCVA ≥ 1.0, ie, a preoperative decimal BCVA of ≥ 0.5. Our findings indicated that the reduction of the FT was significantly lower in the postoperative decimal BCVA ≥ 1.0 group, which was also reasonable because the reduction of FT was significantly correlated with preoperative BCVA (logMAR). On the other hand, although eyes with good preoperative BCVA showed a decreased likelihood of visual improvements, the improvement of the BCVA was significantly higher in the postoperative decimal BCVA ≥ 1.0 group than in the postoperative decimal BCVA \< 1.0 group. The reason for this is unclear. However, the status of the photoreceptor inner and outer segment (IS/OS) or external limiting membrane (ELM) might be one of the explanations for this. The use of a spectral domain OCT would have helped in evaluating the photoreceptor integrity in more detail.

A postoperative decimal BCVA ≥ 1.0 also correlated with a preoperative FT of \<400 μm. We suggest that because the preoperative FT was significantly correlated with the preoperative BCVA and the postoperative BCVA, the postoperative BCVA was worse in eyes with thicker preoperative FT. If the preoperative FT was ≥ 400 μm, the preoperative decimal BCVA might be too low to attain a postoperative decimal BCVA ≥ 1.0, even if the visual improvement was high. Thus, if the effects of the ERM had progressed to cause a lower decimal BCVA and thicker FT, the postoperative visual recovery of decimal BCVA ≥ 1.0 would not be expected, in spite of a larger FT reduction and improvement in BCVA. We conclude that the eyes with both preoperative FT \< 400 μm and preoperative decimal BCVA ≥ 0.5 were the best candidates to obtain a postoperative decimal BCVA of ≥1.0 postoperatively.

The improvement of the BCVA and reduction of the FT following surgery have been reported in the literature.[@b7-opth-5-147],[@b13-opth-5-147]--[@b16-opth-5-147] Several studies have reported that the preoperative FT was significantly correlated with the preoperative BCVA, but the postoperative FT was not significantly correlated with the postoperative BCVA.[@b15-opth-5-147],[@b17-opth-5-147],[@b18-opth-5-147] However, a study by Suh et al reported that the postoperative FT was significantly correlated with the postoperative BCVA after ERM surgery, which is similar to our study.[@b19-opth-5-147] Discrepancies in the association of the postoperative BCVA and FT in earlier studies are probably due to different surgical procedures and low uniformity of various interventions, including ILM removal, dye used, and vitrectomy instruments (20 gauge or 25 gauge). If the ILM was completely removed as in the study by Shimada et al and this study, the residual ILM might not influence the postoperative macular surface to worsen the FT and BCVA.[@b20-opth-5-147]

The removal of the ILM is still controversial because electrophysiological studies have shown some retinal dysfunction following ILM removal and because the use of dye had some retinal toxicity.[@b21-opth-5-147],[@b22-opth-5-147] However, studies have shown a decrease in the recurrences of ERM after ILM peeling and improvement of the BCVA and FT.[@b20-opth-5-147],[@b23-opth-5-147]--[@b25-opth-5-147] Our results showed a 1.4% (1/73 eyes) recurrence rate after more than a mean postoperative period of 9 months.

Because the IS/OS were not evaluated in the study presented, there have been two recent reports that discussed the association between the preoperative OCT images of the IS/OS junction of the photoreceptors and the visual outcomes after ERM surgery.[@b17-opth-5-147],[@b19-opth-5-147] We did not study the IS/OS junction as a prognostic factor because we were not able to precisely detect it because of the low resolution of the OCT we used. In addition, the IS/OS junction is difficult to detect when the FT is thick. Although it is more difficult to detect the ELM by low-resolution OCT, we believe that the BCVA in eyes with ERM would be correlated also with the status of ELM if it could be detected.[@b26-opth-5-147],[@b27-opth-5-147] However, because our results showed that eyes with postoperative decimal BCVA ≥ 1.0 had good preoperative BCVA, and because the nonoperated ERM eyes with photoreceptor defects have significantly lower visual acuity,[@b28-opth-5-147] all of our cases that had a postoperative BCVA ≥ 1.0 probably had a distinct IS/OS junction and ELM in the fovea. Thus, we believe that the preoperative BCVA and FT could be prognostic parameters for all ophthalmologists without knowing precisely the status of the IS/OS junction and even an ELM.

The duration of symptoms was not studied as a prognostic factor[@b28-opth-5-147],[@b29-opth-5-147] because the exact onset of the ERM, especially if the patients had good BCVA, is uncertain.

There are limitations of our study, including its retrospective nature, short follow-up period, small number of patients, and use of time-domain OCT. In addition, although a final decimal BCVA of 1.0 is only one aspect of the visual benefit in ERM surgery, and the degree of visual improvement and reduction of metamorphopsia are also important benefits of this surgery, the aim of this study was to identify factors that led to a postoperative decimal BCVA ≥ 1.0. Nevertheless, our findings indicate that surgery with 25G-TSV/membranectomy for idiopathic ERM is a useful method to obtain good decimal BCVA ≥ 1.0 postoperatively. Based on our study results, a postoperative decimal BCVA of ≥ 1.0 can be achieved in patients whose preoperative decimal BCVA has not deteriorated beyond 0.5 and whose central macular thickness has not exceeded 400 μm. However, many patients in this range of vision and FT are asymptomatic, and we should remember that all surgery carries inherent risks.

In conclusion, our findings indicate that eyes with both preoperative BCVA ≥ 0.5 and FT \< 400 μm have a significantly better chance of obtaining a postoperative decimal BCVA ≥ 1.0 following removal of the idiopathic ERM.
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![Coefficients of correlation between postoperative and preoperative BCVA. The postoperative BCVA at 6 months is significantly correlated with the preoperative BCVA (*r* = 0.44, *P* \< 0.001, Spearman's rank correlation coefficient).\
**Abbreviations:** BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution.](opth-5-147f1){#f1-opth-5-147}

![Coefficients of correlation between postoperative BCVA and preoperative foveal thickness. The postoperative BCVA at 6 months was significantly correlated with the preoperative foveal thickness (r = 0.24, *P* = 0.04, spearman's rank correlation coefficient).\
**Abbreviations:** BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution.](opth-5-147f2){#f2-opth-5-147}

###### 

Summary of clinical data

  **Characteristics**               **Value**     ***P* value**
  --------------------------------- ------------- ----------------------------------------------------
  Eyes (no.)                        73            
  Patients (no./%)                  73            
    Male                            24 (33)       
    Female                          49 (67)       
  Age (yrs)                                       
    Mean ± SD                       67.2 ± 10.4   
    Median                          68            
    Range                           28--87        
  Lens status (baseline; no./%)                   
    Phakic                          61 (84)       
    Pseudophakic                    12 (16)       
  Surgical procedure (no./%)                      
    25G-TSV                         34 (47)       
    Triple surgery                  39 (53)       
  Decimal BCVA (mean)                             
    Baseline                        0.59          
    Postoperative 6M                0.74          
  BCVA (logMAR; mean ± SD)                        
    Baseline                        0.23 ± 0.25   
    Postoperative 6M                0.13 ± 0.27   \<0.001[\*](#tfn2-opth-5-147){ref-type="table-fn"}
    Improvement                     0.10 ± 0.21   
  Foveal thickness (μm; mean (SD)                 
    Baseline                        371 ± 106     
    Postoperative 6M                300 ± 67      \<0.001[\*](#tfn2-opth-5-147){ref-type="table-fn"}
    Reduction                       71 ± 43       

**Notes:**

Wilcoxon signed--rank test, Postoperative 6M versus baseline. Triple surgery, phaceomulsification and aspiration, intraocularlens implant, and 25-gauge transconjunctival sutureless vitrectomy.

**Abbreviations:** SD, standard deviation; 25G-TSV, 25-gauge transconjunctival sutureless vitrectomy; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution.

###### 

Correlation between visual acuity and foveal thickness

                                           **r value**   ***P* value**
  -------------------- ------------------- ------------- ----------------------------------------------------
  Reduction of FT      Preoperative FT     0.80          \<0.001[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Visual improvement   Preoperative BCVA   0.55          \<0.001[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Postoperative BCVA   Preoperative BCVA   0.44          \<0.001[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Preoperative BCVA    Preoperative FT     0.43          \<0.001[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Reduction of FT      Preoperative BCVA   0.31          0.008[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Postoperative BCVA   Postoperative FT    0.26          0.03[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Visual improvement   Reduction of FT     0.24          0.04[\*](#tfn5-opth-5-147){ref-type="table-fn"}
  Postoperative BCVA   Preoperative FT     0.24          0.04[\*](#tfn5-opth-5-147){ref-type="table-fn"}

**Notes:**

Spearman's correlation coefficient by rank. Reduction of FT, preoperative FT -- postoperative FT; Visual improvement, preoperative BCVA -- postoperative BCVA in logMAR units.

**Abbreviations:** FT, foveal thickness (μm); BCVA, best-corrected visual acuity in logarithm of the minimum angle of resolution (logMAR).

###### 

Association between preoperative decimal best-corrected visual acuity and postoperative decimal best-corrected visual acuity ≥1.0

  **Preoperative decimal BCVA**   **Eyes, no.**   **Postoperative 6M decimal BCVA ≥ 1.0, no (%)**
  ------------------------------- --------------- -------------------------------------------------
  ≥0.9                            21              12 (57)
  0.7--0.8                        15              7 (47)
  0.5--0.6                        18              8 (44)
  0.3--0.4                        15              2 (13)
  0.1--0.2                        2               0 (0)
  ≤0.09                           2               0 (0)
  Total                           73              29 (40)

**Notes:** *P* = 0.002, Fisher's exact probability test, ≥0.5 versus \<0.5; *P* = 0.008, Fisher's exact probability test, ≥0.9 versus 0.3--0.4; *P* = 0.05, Fisher's exact probability test, 0.7--0.8 versus 0.3--0.4; *P* = 0.06, Fisher's exact probability test, 0.5--0.6 versus 0.3--0.4; *P* = 0.21, Fisher's exact probability test, ≥0.9 versus 0.5--0.6; *P* = 0.39, Fisher's exact probability test, ≥0.9 versus 0.7--0.8; *P* = 0.46, Fisher's exact probability test, 0.7--0.8 versus 0.5--0.6.

**Abbreviation:** BCVA, best-corrected visual acuity.

###### 

Association between preoperative foveal thickness and postoperative decimal best-corrected visual acuity ≥1.0

  **Preoperative foveal thickness (μm)**   **Eyes, no.**   **Postoperative 6M decimal BCVA ≥ 1.0, no (%)**
  ---------------------------------------- --------------- -------------------------------------------------
  ≥400                                     28              6 (21)
  300--399                                 25              14 (56)
  200--299                                 19              9 (47)
  100--199                                 1               0 (0)
  Total                                    73              29 (40)

**Notes:** *P* = 0.01, Fisher's exact probability test, ≥400 μm versus \<400 μm; *P* = 0.01, Fisher's exact probability test, ≥400 μm versus 300--399 μm; *P* = 0.06, Fisher's exact probability test, ≥400 μm versus 200--299 μm; *P* = 0.40, Fisher's exact probability test, 300--399 μm versus 200--299 μm.

**Abbreviation:** BCVA, best-corrected visual acuity.

###### 

Association between preoperative findings and postoperative decimal best-corrected visual acuity ≥1.0

  **Group**   **Preoperative findings**           **Eyes, no.**   **Postoperative 6M decimal BCVA ≥ 1.0, no (%)**
  ----------- ----------------------------------- --------------- -------------------------------------------------
  1           Decimal BCVA ≥ 0.5 and FT \< 400    40              24 (60)
  2           Decimal BCVA ≥ 0.5 and FT ≥400      10              2 (20)
  3           Decimal BCVA \< 0.5 and FT \< 400   8               2 (25)
  4           Decimal BCVA \< 0.5 and FT ≥400     15              1 (7)
              **Total**                           73              29 (40)

*P* = 0.03, Fisher's exact probability test, Group 1 versus Group 2.

*P* = 0.08, Fisher's exact probability test, Group 1 versus Group 3.

*P* \< 0.001, Fisher's exact probability test, Group 1 versus Group 4.

*P* = 0.62, Fisher's exact probability test, Group 2 versus Group 3.

*P* = 0.35, Fisher's exact probability test, Group 2 versus Group 4.

*P* = 0.27, Fisher's exact probability test, Group 3 versus Group 4.

**Abbreviations:** BCVA = best-corrected visual acuity; FT = foveal thickness (μm).

###### 

Summary of clinical data by postoperative decimal best-corrected visual acuity ≥1.0 or \<1.0

                                     **Postoperative decimal BCVA ≥ 1.0**   **Postoperative decimal BCVA** \< **1.0**   ***P* value**
  ---------------------------------- -------------------------------------- ------------------------------------------- -----------------------------------------------------
  No. eyes                           29                                     44                                          
  No. patients                       29                                     44                                          
  Gender (no./%)                                                                                                        0.08[\*](#tfn19-opth-5-147){ref-type="table-fn"}
    Male                             13 (45)                                11 (25)                                     
    Female                           16 (55)                                33 (75)                                     
  Age (yrs)                                                                                                             
    Mean ± SD                        65.9 ± 12.8                            68.1 ± 8.5                                  0.57[\#](#tfn20-opth-5-147){ref-type="table-fn"}
    Median                           68                                     67                                          
    Range                            27--87                                 50--82                                      
  Lens status (baseline; no./%)                                                                                         0.69[\*](#tfn19-opth-5-147){ref-type="table-fn"}
    Phakic                           24 (83)                                37 (84)                                     
    Pseudophakic                     5 (17)                                 7 (16)                                      
  Surgical procedure (no./%)                                                                                            0.35[\*](#tfn19-opth-5-147){ref-type="table-fn"}
    25G-TSV                          14 (48)                                18 (36)                                     
    Triple surgery                   15 (52)                                26 (64)                                     
  Decimal BCVA (mean)                                                                                                   
    Baseline                         0.74                                   0.50                                        
    Postoperative 6M                 1.10                                   0.56                                        
  BCVA (logMAR; mean ± SD)                                                                                              
    Baseline                         0.13 ± 0.15                            0.30 ± 0.29                                 0.004[\#](#tfn20-opth-5-147){ref-type="table-fn"}
    Postoperative 6M                 −0.04 ± 0.07                           0.25 ± 0.29                                 \<0.001[\#](#tfn20-opth-5-147){ref-type="table-fn"}
    Improvement                      0.18 ± 0.15                            0.05 ± 0.23                                 0.01[\#](#tfn20-opth-5-147){ref-type="table-fn"}
  Foveal thickness (μm; mean ± SD)                                                                                      
    Baseline                         344 ± 73                               389 ± 121                                   0.07[\#](#tfn20-opth-5-147){ref-type="table-fn"}
    Postoperative 6M                 283 ± 39                               312 ± 78                                    0.11[\#](#tfn20-opth-5-147){ref-type="table-fn"}
    Reduction                        61 ± 35                                77 ± 48                                     \<0.001[\#](#tfn20-opth-5-147){ref-type="table-fn"}

**Notes:**

Fisher's exact probability test;

Mann--Whitney test. Triple surgery, phacoemulsification and aspiration, intraocular lens implant, and 25-gauge transconjunctival sutureless vitrectomy.

**Abbreviations:** SD, standard deviation; 25G-TSV, 25-gauge transconjunctival sutureless vitrectomy; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution.
